Your browser doesn't support javascript.
loading
Population-Based Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza Infection in Southern China, 2023-2024 Season.
Gào, Xin; Sun, Yexiang; Shen, Peng; Guo, Jinxin; Chen, Yunpeng; Yin, Yueqi; Liu, Zhike; Zhan, Siyan.
Afiliación
  • Gào X; Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.
  • Sun Y; Key Laboratory of Epidemiology of Major Diseases, Peking University, Ministry of Education, Beijing, China.
  • Shen P; Yinzhou District Center for Disease Control and Prevention, Ningbo, China.
  • Guo J; Yinzhou District Center for Disease Control and Prevention, Ningbo, China.
  • Chen Y; Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.
  • Yin Y; Key Laboratory of Epidemiology of Major Diseases, Peking University, Ministry of Education, Beijing, China.
  • Liu Z; Yinzhou District Center for Disease Control and Prevention, Ningbo, China.
  • Zhan S; Yinzhou District Center for Disease Control and Prevention, Ningbo, China.
Open Forum Infect Dis ; 11(9): ofae456, 2024 Sep.
Article en En | MEDLINE | ID: mdl-39220659
ABSTRACT

Background:

In China, the 2022-2023 influenza season began earlier and was characterized by higher levels of influenza activity and co-circulation of various respiratory pathogens compared with seasons before the coronavirus disease 2019 (COVID-19) pandemic. Timely and precise estimates of influenza vaccine effectiveness (IVE) against infections can be used to guide public health measures.

Methods:

A test-negative study was conducted to estimate IVE against laboratory-confirmed influenza using data from the CHinese Electronic health Records Research in Yinzhou (CHERRY) study that prospectively integrated laboratory, vaccination, and health administrative data in Yinzhou, southern China. We included patients who presented influenza-like illness and received nucleic acid tests and/or antigen tests between October 2023 and March 2024. Estimates of IVE were adjusted for age, gender, month of specimen submitted, chronic comorbidities, and hospitalization status.

Results:

A total of 205 028 participants, including 96 298 influenza cases (7.6% vaccinated) and 108 730 influenza-negative controls (13.4% vaccinated), were eligible for this analysis. The estimates of IVE were 49.4% (95% CI, 47.8%-50.9%), 41.9% (95% CI, 39.8%-44.0%), and 59.9% (95% CI, 57.9%-61.9%) against overall influenza, influenza A, and influenza B, respectively. A lower IVE was observed for individuals aged 7-17 years (38.6%), vs 45.8% for 6 months-6 years, 46.7% for 18-64 years, and 46.1% for ≥65 years. Vaccination reduced the risk of infection by 44.4% among patients with chronic comorbidities. IVEs varied by epidemic weeks with the changes in influenza activity levels and the switch of dominant influenza strains.

Conclusions:

Influenza vaccination in the 2023-2024 season was protective against infection for the entire population.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Open Forum Infect Dis Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Open Forum Infect Dis Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos